Q2 2021 13F Holders as of 30 Jun 2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
77,331,078
-
Number of holders
-
99
-
Total 13F shares, excl. options
-
33,296,183
-
Shares change
-
+133,234
-
Total reported value, excl. options
-
$619,964,580
-
Value change
-
+$2,566,015
-
Put/Call ratio
-
12.3%
-
Number of buys
-
41
-
Number of sells
-
-33
-
Price
-
$18.62
Significant Holders of Xenon Pharmaceuticals Inc. - Common Stock (XENE) as of Q2 2021
108 filings reported holding XENE - Xenon Pharmaceuticals Inc. - Common Stock as of Q2 2021.
Xenon Pharmaceuticals Inc. - Common Stock (XENE) has 99 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 33,296,183 shares
of 77,331,078 outstanding shares and own 43.06% of the company stock.
Largest 10 shareholders include Avoro Capital Advisors LLC (3,650,000 shares), FMR LLC (3,072,444 shares), PERCEPTIVE ADVISORS LLC (1,678,973 shares), BVF INC/IL (1,571,778 shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (1,525,000 shares), EVENTIDE ASSET MANAGEMENT, LLC (1,490,000 shares), ORBIMED ADVISORS LLC (1,334,217 shares), Capital International Investors (1,055,726 shares), CITADEL ADVISORS LLC (1,043,543 shares), and NEA Management Company, LLC (992,107 shares).
This table shows the top 99 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.